1
|
Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol 2023; 78:e131-e136. [PMID: 36344282 DOI: 10.1016/j.crad.2022.09.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 09/06/2022] [Accepted: 09/29/2022] [Indexed: 11/06/2022]
Abstract
AIM To assess the frequency of radiographically evident drug-induced sarcoidosis-like reaction (DISR) in patients treated with anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) therapy, anti-programmed cell death protein 1 (PD-1) therapy, or a combination of both in a single centre. MATERIALS AND METHODS The images and medical records of 457 patients with metastatic melanoma or head and neck cancer treated with either anti-CTLA-4 therapy, anti-PD-1 therapy, or a combination of both at University of California medical centre were reviewed retrospectively and the incidence of radiological manifestations of DISR was assessed among these treatment groups. RESULTS Radiological manifestations of DISR were found in 19/457 patients (4.1%). The mean interval from the initiation of immunotherapy to development of DISR was 5.5 months (range 2.3-13.5 months). Mean interval from radiological detection of DISR to imaging evidence of resolution was 5.8 months (range 1.6-18.3 months). Three patients out of 81 (3.7%), 11/297 (3.7%), and 5/79 (6.3%) developed sarcoidosis-like reaction after treatment with anti-CTLA-4 antibody, anti-PD-1 antibody, and a combination of both, respectively. Most patients with DISR were asymptomatic and did not require systemic therapy. Most patients did not demonstrate concomitant increased maximum standardised uptake value (SUVmax) in other organs on their integrated 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT). CONCLUSIONS In the present retrospective study of patients treated with immune checkpoint inhibitors (ICIs), DISR occurred in approximately 3.7% of patients treated with either anti-CTLA-4 or anti-PD-1 antibody and 6.3% of patients treated with a combination of both.
Collapse
Affiliation(s)
- Y Li
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
| | - R R Flavell
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
| | - R Juarez
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
| | - M Chow
- Department of Medicine, University of California, San Francisco, 1825 5(th) St, San Francisco, CA 94143, USA
| | - C Wu
- Department of Medicine, University of California, San Francisco, 1825 5(th) St, San Francisco, CA 94143, USA
| | - K Tsai
- Department of Medicine, University of California, San Francisco, 1825 5(th) St, San Francisco, CA 94143, USA
| | - A Daud
- Department of Medicine, University of California, San Francisco, 1825 5(th) St, San Francisco, CA 94143, USA
| | - S C Behr
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA.
| |
Collapse
|
2
|
Lebbe C, Long G, Robert C, Hamid O, Atkinson V, Shoushtari A, Daud A, Bechter O, Schadendorf D, Sullivan R, Dummer R, Grob J, Lewis N, Fan L, Basu S, Caponigro G, Cooke V, Lau A, Amaria R. LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Saleh M, Wahid I, Daud A, Mallongi A, Russeng SS. The Potential Test of the Mosquito Oviposition Preference Using Similar Subtracts: Colonized Water and Aides Larvae Extract. Open Access Maced J Med Sci 2022. [DOI: 10.3889/oamjms.2022.8184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The research on ovitrap using attractants have been extensively developed, but studies on the use of similar substrates in the form of colonized water and Aedes larvae extract as attractants have not been widely published. Adding an attractant to the ovitrap can stimulate the sense of smell for mosquitoes to come to the place to lay their eggs. The use of ovitrap has recently begun to be developed because it is environmentally friendly. The purpose of this study is to determine the attractants potential of colonized water and larvae extract as the oviposition preferences for of Aedes Sp. to lay eggs in the ovitrap. The type of this research is a true experimental design, the design of The Posttest-Only Control Group Design. Observations are made in the laboratory for nine repetitions. Observational data show that the average number of eggs in ovitraps that uses the colonized water and larvae extract is higher than that of conventional/control water. The results of the Kruskal-Wallis test indicate that there is a significant difference in the average number of eggs in the colonized water attractant, larval extract and conventional water (Asymp. Sig < 0.05). The conclusion is obtained that similar substrate attractants in the form of larvae extract and Aedes colonization water have the potential to be Aedes sp oviposition preferences compared to conventional water. However, it is still necessary to conduct a field study so that it can be used as an environmentally friendly method of the surveillance and control of the vector transmitting Dengue Hemorrhagic Fever.
Collapse
|
4
|
Ariyanto J, Palutturi S, Russeng SS, Birawida AB, Denny H, Daud A, Arsin A, Wahyu A. Prediction and Control Model of Musculoskeletal Disorders in the Instant Noodle Company in Makassar 2020–2050. Open Access Maced J Med Sci 2022. [DOI: 10.3889/oamjms.2022.7897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND: There are many risk factors that result in musculoskeletal disorders because of work. This also occurs in the instant food industry, where apart from manual load handling and repetitive work, the production process can also results in risks.
AIM: The aims of this study are to predict the musculoskeletal disorders in the next 50 years and the effectiveness of scenarios for controlling musculoskeletal disorders.
METHODS: This study employed Research and Development method through a dynamics system approach. This research was conducted in one of the industries that produce instant food in South Sulawesi, Indonesia. The data obtained was based on interviews, which were further analyzed using Interpretative Structural Modeling.
RESULTS: Based on the simulation results for 30 years, it was found that there was an increase in the average musculoskeletal disorder incidence by 20.63% per year. At the end of the simulation in 2050, the number of musculoskeletal disorder incidents became 48481.69. In this case, the simulation for 30 years (2020–2050) was conducted on a model of controlling occupational diseases at an instant noodle company in Makassar by providing treatment in the form of reducing risk factors that cause musculoskeletal disorders. Based on the simulation results for 30 years (2020–2050), musculoskeletal disorders have the most significant contribution to the increase of occupational diseases incidents as a whole. The increase in musculoskeletal disorders is an accumulation of several risk factors that exist in the instant noodle production process.
CONCLUSIONS: Prediction of the musculoskeletal disorder incidence using a dynamic system approach for 30 years (2020–2050) has increased by an average of 20.63% per year. The behavior of the model after receiving treatment on the occurrence of musculoskeletal disorders has an average decrease in the average incidence of 51.11% per year. In this case, to control the musculoskeletal disorder incidence, the elements or variables controlled simultaneously are work posture, lifting load, and length of work.
Collapse
|
5
|
Budiman, Ishak H, Stang, Ibrahim E, Daud A, Amiruddin R. Essential oil as a new tool for larvicidal Aedes aegypti: A systematic review. Gac Sanit 2021; 35 Suppl 2:S459-S462. [PMID: 34929875 DOI: 10.1016/j.gaceta.2021.10.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 07/30/2021] [Indexed: 10/19/2022]
Abstract
OBJECTIVE The study aimed to describe the effectiveness of essential oil plants for Aedes aegypti mosquito vector control. METHODS This systematic review selection process following with 2015 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guideline. The source of the articles from databases international journal were Scopus, Pubmed, Scinapse and Google Scholar. RESULT Natural control management with essential oil is the way of alternative for larvicidal mosquito control especially A. aegypti. The essential oil for many plants can use for larvicidal against A. aegypti as Piper batle L., Tinospora rhumpii, Azadiractha indica, Persea americana, Piper aduncum, Leucas aspera, Eucaliptus camaldulensis, Ottonia anisum, Salvia Plebeian, Lantana camara, and Syzygium aromaticum with 100% mortality larvae A. aegypti at 48h. CONCLUSIONS The vector borne diseases must be used to integrate vector management control with essential oils plants.
Collapse
Affiliation(s)
- Budiman
- Faculty of Public Health, Muhammadiyah University, Palu, Indonesia; Faculty of Public Health, Hasanuddin University, Makassar, Indonesia.
| | - Hasanuddin Ishak
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Stang
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Erniwati Ibrahim
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Anwar Daud
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Ridwan Amiruddin
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| |
Collapse
|
6
|
Purimahua SL, Arsin AA, Daud A, Thaha RM, Darmawangsa, Birawida AB. Biomarkers of pneumonia disease in under five children in "grill culture". Gac Sanit 2021; 35 Suppl 2:S435-S437. [PMID: 34929870 DOI: 10.1016/j.gaceta.2021.10.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 07/30/2021] [Indexed: 10/19/2022]
Abstract
OBJECTIVE Based on data WHO in 2018, almost 802,200 cases of pneumonia occur in children. Indonesia data on Riskesdas in 2018, the increase in pneumonia with the prevalence of pneumonia based on the age group 1-4 years was 5.0. This study aims to obtain more information about biomarkers of the clinical assessment on patient cases and prevention management and then whether postpartum culture contributed to the increase in pneumonia. METHODS The method used is a Literature review. Search for scientific articles collected through Scopus indexed journals through Science Direct, Pubmed, Elsevier, MDPI, WHO, Riskesdas, Google Scholar. RESULT From the literature articles we read, it shows that the incidence of pneumonia increases from year to year and is the leading cause of death. So it needs prevention from use biomarkers as markers and examined the association of Grill Culture with pneumonia in children under five. CONCLUSION The results of the biomarker examination are a marker of the case and prevention management will be carried out using existing cultural approaches.
Collapse
Affiliation(s)
- Sintha Lisa Purimahua
- Graduated Student of Public Health, Hasanuddin University, Makassar 90245, Indonesia; Faculty of Public Health, Nusa Cendana University, Kupang 85001, Indonesia.
| | - A Arsunan Arsin
- Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia
| | - Anwar Daud
- Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia
| | - Ridwan M Thaha
- Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia
| | - Darmawangsa
- Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia
| | | |
Collapse
|
7
|
Rauf AU, Mallongi A, Lee K, Daud A, Hatta M, Al Madhoun W, Astuti RDP. Potentially Toxic Element Levels in Atmospheric Particulates and Health Risk Estimation around Industrial Areas of Maros, Indonesia. Toxics 2021; 9:toxics9120328. [PMID: 34941762 PMCID: PMC8708896 DOI: 10.3390/toxics9120328] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 11/23/2021] [Accepted: 11/25/2021] [Indexed: 11/18/2022]
Abstract
Air quality deterioration is a major environmental problem in Indonesia. This study evaluated the levels and health risks of potentially toxic elements (PTEs) in Maros Regency, Indonesia. Total suspended particulate matter was collected from industrial areas for PTE (Al, Pb, Cr, Cu, Ni, As and Zn) analysis using inductively coupled plasma optical emission spectrometry (ICP-OES). Samples were collected from six critical areas in the Bantimurung region as that is where marble, cement and limestone industries are located. A calculation of the non-carcinogenic and cancer risks was performed to determine the potential health exposures in adults and children. A Monte Carlo simulation with 10,000 iterations and a sensitivity analysis was carried out to identify the risk probability and the most sensitive variable contributing to cancer risk from PTE exposure in humans. The results showed that the concentration of PTEs decreased in the order of Zn > Al > Cr > Pb > Cu > Ni > As in the wet season, and Zn > Al > Pb > As > Cr > Cu > Ni in the dry season. The hazard index (HI) value for children was 2.12, indicating a high non-carcinogenic risk for children. The total cancer risk (TCR) values in adults and children were 3.11 × 10−5 and 1.32 × 10−4, respectively, implying that both are at risk for developing cancer. The variables with the most contribution to cancer risk from As, Cr and Pb exposure in adults and children were As concentration (33.9% and 41.0%); exposure duration (ED) (34.3%) and SA (40.7%); and SA (98.7 % and 45.4%), respectively. These findings could be used as the scientific basis for public health intervention and to raise awareness of the harmful health effects of particulate bound PTEs
Collapse
Affiliation(s)
- Annisa Utami Rauf
- Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia; (A.U.R.); (A.D.); (R.D.P.A.)
| | - Anwar Mallongi
- Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia; (A.U.R.); (A.D.); (R.D.P.A.)
- Correspondence:
| | - Kiyoung Lee
- Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul 08826, Korea;
| | - Anwar Daud
- Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia; (A.U.R.); (A.D.); (R.D.P.A.)
| | - Muhammad Hatta
- Marine Science Department, Faculty of Marine Science and Fisheries, Hasanuddin University, Makassar 90245, Indonesia;
| | | | - Ratna Dwi Puji Astuti
- Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar 90245, Indonesia; (A.U.R.); (A.D.); (R.D.P.A.)
| |
Collapse
|
8
|
Basri K S, Daud A, Astuti RDP, K B. Detection of Exposure to Microplastics in Humans: A Systematic Review. Open Access Maced J Med Sci 2021. [DOI: 10.3889/oamjms.2021.6494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND: Microplastics are able to enter the human body through food chains, personal care products, contact (skin) from the soil, water or inhalation of microplastics in the air.
AIM: This article aims to identify the presence of microplastics that are exposed to humans.
METHODS: Systematic review using four bibliographic databases (Google Scholar, Wiley Online Library, PubMed, and Science Direct). Literature search from 2016 to 2021, in the search found as many as 10983 papers extracted using PRISMA guidelines, a total of five papers were selected for review.
RESULTS: In this review article, the presence of oral, dermal, and inhalation exposed microplastics is found in feces, colon, placenta, scalp hair, hand skin, facial skin, and saliva. Several methods are used to identify microplastics according to polymer types, shape, and sizes microplastics in humans. The polymer type often found in the article is polypropylene. In addition, fibers, fragments and films are detectable shape of microplastic, while the size of microplastics >5 mm.
CONCLUSION: This literature study provides evidence that microplastics of various types of polymers, shapes and sizes are ubiquitous in humans. Hence, the possibility of health risks resulting from microplastic exposure in the human body should not be ignored.
Collapse
|
9
|
Rauf AU, Mallongi A, Daud A, Hatta M, Al-Madhoun W, Amiruddin R, Rahman SA, Wahyu A, Astuti RDP. Community Health Risk Assessment of Total Suspended Particulates near a Cement Plant in Maros Regency, Indonesia. J Health Pollut 2021; 11:210616. [PMID: 34268002 PMCID: PMC8276719 DOI: 10.5696/2156-9614-11.30.210616] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 04/17/2021] [Indexed: 04/14/2023]
Abstract
BACKGROUND Cement plants generate particulate matter (PM) across processes from raw material preparation to packaging. The presence of total suspended particulates (TSP) coming out of the stack causes a high accumulation of dust in residential areas. Human exposure to TSP could affect human health and wellbeing. OBJECTIVES The present study aims to evaluate concentrations of TSP and to estimate the health risks of TSP exposure through the inhalation pathway in communities surrounding a private cement industry in Maros regency, Indonesia. METHODS Total suspended particulates were collected using a high-volume air sampler (HVAS) at five locations. Samples were taken by grab sampling for 24 hours. The SCREEN3 program was used to view the maximum range and distribution of pollutants based on the geographical, stack profiles and meteorological factors in the study area. Hazard quotient (HQ) was used to estimate non-carcinogenic risks of TSP in surrounding communities. RESULTS Total suspended particulate concentrations were measured with a maximum value of 133.24 μg/m3 and a minimum value of 18.48 μg/m3. This maximum value exceeds the minimum acceptable level from Canadian National Ambient Air Quality Objectives (C-NAAQOs). The non-carcinogenic risks from the inhalation pathway were low except for location 3 (HQ>1) across all locations. CONCLUSIONS The cement plant may significantly contribute to total TSP concentrations in air and may potentially have adverse effects on human health. Communities near the cement plant are vulnerable to TSP exposure and measures are needed to reduce TSP in Maros regency, Indonesia. PARTICIPANT CONSENT Obtained. ETHICS APPROVAL This study was approved by the Health Research Ethics Committee of Hasanuddin University with protocol number 28920093022. COMPETING INTERESTS The authors declare no competing financial interests.
Collapse
Affiliation(s)
- Annisa Utami Rauf
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Anwar Mallongi
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Anwar Daud
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Muhammad Hatta
- Faculty of Marine Science and Fisheries, Hasanuddin University, Makassar, Indonesia
| | - Wesam Al-Madhoun
- Faculty of Civil Engineering and Built Environment, Universiti Tun Hussein Onn Malaysia, Malaysia
| | - Ridwan Amiruddin
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | | | - Atjo Wahyu
- Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | | |
Collapse
|
10
|
Daud A, Kesete B, Sriranjan S, Britton E, Steel C, Lewin J. Evaluation of efficiency and quality of the multi-disciplinary team handover process in a mother and baby inpatient setting. Eur Psychiatry 2021. [PMCID: PMC9475588 DOI: 10.1192/j.eurpsy.2021.1339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Introduction At Coombe Wood Mother and Baby unit (MBU) there are daily multi-disciplinary team (MDT) handover meetings and a weekly MDT ward round attended by 7-8 team members. There are concerns that the handover is too time consuming, utilising time which could be spent on other clinical duties, and concerns regarding the relevance of information that is handed over. Objectives To perform a service evaluation to determine the efficiency and quality of MDT handover meetings in an MBU setting. Methods Data was collected from September to October 2020. A checklist was designed listing information felt to be relevant to handover and contained the following data points – ‘current situation’, ‘mental health’, ‘level of observations’, ‘risk’, ‘physical health’, ‘baby care’, ‘baby supervision levels’ and ‘tasks and responsibilities’. The start and stop times of each MDT handover meeting were noted and a record was made as to whether these topics were discussed. Results Mean meeting duration was 32.2 minutes (range: 13 – 45 minutes) and amounted to 2.68 hours spent in MDT handover over a 5-day working week. This equates to 21.4 person-hours (based on 8 staff) a week. 928 data points were generated. 50.7% (468) data points were recorded and commonly omitted data points were – ‘tasks and responsibilities’, ‘risk’, ‘level of observations’ and ‘physical health’. On all occasions, ‘current situation’, ‘mental health’ and ‘baby care’ were handed over. Conclusions The results of this service evaluation provide compelling evidence for a wider improvement project. Involving MDT staff in designing interventions will make handover meetings more meaningful.
Collapse
|
11
|
Rauf AU, Mallongi A, Daud A, Hatta M, Astuti RDP. Ecological risk assessment of hexavalent chromium and silicon dioxide in well water in Maros Regency, Indonesia. Gac Sanit 2021; 35 Suppl 1:S4-S8. [PMID: 33832623 DOI: 10.1016/j.gaceta.2020.12.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 12/04/2020] [Indexed: 12/07/2022]
Abstract
OBJECTIVE This paper assesses the potential ecological risk of hexavalent chromium (Cr(VI)) and silicon dioxide/silica (SiO2) in well water. Both of pollutants have been classified as carcinogenic compound. The ecological risk assessment of drinking water is an effective tool to evaluate drinking water quality to reduce further risk. METHOD Fourteen well water samples were collected around the residential area near cement industrial activity and karst mining area. Estimating the ecological risk of well water which consumed daily evaluated based on Hazard Quotient (HQ) ratio. RESULTS The mean values of Cr(VI) and SiO2 in well water samples were 0.0017mg/L and 12.94mg/L, respectively. Drinking water in this area are unacceptable. HQ values for SiO2 at all stations are more than 1 (moderate level). CONCLUSIONS Cr(VI) and SiO2 are discoverable within well water surrounding the research location. This finding is used as scientific data and references for ecological protection of drinking water in Maros.
Collapse
Affiliation(s)
- Annisa Utami Rauf
- Doctoral Program of Public Health, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia.
| | - Anwar Mallongi
- Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Anwar Daud
- Department of Environmental Health, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| | - Muhammad Hatta
- Department of Marine Science, Faculty of Marine Science and Fisheries, Hasanuddin University, Makassar, Indonesia
| | - Ratna Dwi Puji Astuti
- Doctoral Program of Public Health, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
| |
Collapse
|
12
|
Suhelmi R, Amqam H, Thaha RM, Mallongi A, Daud A, Ishaq H. The relationship of mercury exposure with neurological problems in artisanal gold in Makassar city. Rev Environ Health 2020; 35:265-269. [PMID: 32712592 DOI: 10.1515/reveh-2020-0034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2020] [Accepted: 06/04/2020] [Indexed: 06/11/2023]
Abstract
Objectives This research aims to analyse the relationship between urine mercury levels and neurological problems. Methods This research is an observational study with a cross-sectional approach. There are 44 goldsmiths in the gold jewellery small scale industry involved in this study. Urine mercury levels were measured using an atomic absorption spectrophotometer. Neurological problems were assessed by a medician. Data collected includes age, time of exposure, work duration, smoking behaviour and nutrition status of the goldsmiths which were obtained by interview. Results The results showed that the concentration of mercury in the goldsmith's urine was around 0.93-64.59 μg/L. The analysis showed that there were 63% of goldsmiths experiencing neurological problems, such as tremors (9.1%) and knee pass reflex (6.8%). The bivariate analysis showed that there is no significant relationship between the concentration of mercury (p=0.133), age (p=0.155), time of exposure (p=0.702), time of working (p=0.354), smoking behaviour (p=0.169) and nutrition status (p=0.541) with neurological problems. Conclusions The goldsmiths who had high levels of mercury in urine samples were diagnosed with at least one of the neurological symptoms. It is recommended that the goldsmith use personal protective equipment during work such as mask, glasses and gloves.
Collapse
Affiliation(s)
- Reni Suhelmi
- Environmental Health Department of Universitas Muhammadiyah Kalimantan Timur, Samarinda, Indonesia
| | - Hasnawati Amqam
- Environmental Health Department, Public Health, Universitas Hasanuddin, Makassar, Indonesia
| | - Ridwan M Thaha
- Health Promotion and Behavioral Science Department, Public Health, Universitas Hasanuddin, Makassar, Indonesia
| | - Anwar Mallongi
- Environmental Health Department, Public Health, Universitas Hasanuddin, Makassar, Indonesia
| | - Anwar Daud
- Environmental Health Department, Public Health, Universitas Hasanuddin, Makassar, Indonesia
| | - Hasanuddin Ishaq
- Environmental Health Department, Public Health, Universitas Hasanuddin, Makassar, Indonesia
| |
Collapse
|
13
|
Kur’aini SN, Razak A, Daud A, Mallngi A. Economic Status of Community Interest in Membership of BPJS Health in Duampanua District, Pinrang Regency. Open Access Maced J Med Sci 2020. [DOI: 10.3889/oamjms.2020.5180] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND: Starting from 2017 until 2019, the number of patient visiting public health centers Lampa is always more than the number of patient visits BPJS, it indicates that the public interest in District Duampanua, Pinrang Regency on BPJS Health membership is still lacking.
AIM: This study aimed to determine the effect of economic status on community interest in BPJS health membership.
METOHDS: This study used a quantitative research with cross-sectional study approach. The location of this research was in the District Duampanua, Pinrang Regency. The population in this study is the community in Duampanua District Pinrang Regency with 51.593 people. The sampling technique in this study used a purposive sampling technique with 100 sample size. Data analysis performed was univariate and bivariate with Chi-square test.
RESULTS: The results showed that there are influence of economic status variables (p = 0.016) to community interest in BPJS Health membership in Duampanua District, Pinrang Regency. The conclusion of this study is that there is an influence of economic status on community interest in BPJS Health membership because the higher the economic status of the community, the higher their interest in BPJS Health membership.
CONCLUSION: It is expected that stakeholders in each village in the Duampanua District can find out the income of the community by conducting data collection evenly as proof of their worthiness of being members of JKN-KIS participants.
Collapse
|
14
|
Wisudawan B. O, Mallongi A, Russeng SS, Hatta M, Daud A, Subhan M. Bioaerosol pollution in intensive-care unit of Dr. Wahidin Sudirohusodo Hospital Makassar: Morning and midday assessment. Enfermería Clínica 2020. [DOI: 10.1016/j.enfcli.2020.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Ekasulistyawaty, Syafar M, Daud A, Arsunan Arsin A, Mallongi A, Werdyaningsih E. Change of behavior of ODF through STBM Program in Cempaka Putih Village North Gorontalo Regency. Enfermería Clínica 2020. [DOI: 10.1016/j.enfcli.2019.10.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
16
|
Harun H, Daud A, Hadju V, Arief CPP, Talebe T, Rahma, Wahyuni RD, Sumarni, Miranti, Amri I, Faris A, Mallongi A. Antioxidant effect of Moringa oleifera leaves in hemoglobin oxidation compare with vitamin C. Enfermería Clínica 2020. [DOI: 10.1016/j.enfcli.2019.10.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Eggermont A, Carlino M, Hauschild A, Ascierto P, Arance A, Daud A, O’Day S, Taylor M, Smith A, Rodgers A, Moreno BH, Diede S, Kluger H. Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30:582-588. [PMID: 30715153 PMCID: PMC6503622 DOI: 10.1093/annonc/mdz011] [Citation(s) in RCA: 562] [Impact Index Per Article: 112.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. CONCLUSIONS This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY ClinicalTrials.gov, NCT01295827.
Collapse
Affiliation(s)
- O Hamid
- Medical Oncology, The Angeles Clinic and Research Institute, Los Angeles, USA.
| | - C Robert
- Department of Dermatology, Gustave Roussy, Villejuif; Department of Medicine, University of Paris-Sud, Paris, France
| | - A Daud
- Department of Medicine, University of California, San Francisco, San Francisco
| | - F S Hodi
- Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - W J Hwu
- Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R Kefford
- Medical Oncology, Westmead Hospital, Westmead; Medical Oncology, Melanoma Institute Australia, Sydney; Medical Oncology, Macquarie University, Macquarie Park; Medical Oncology, University of Sydney, Sydney, Australia
| | - J D Wolchok
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - P Hersey
- Medical Oncology, University of Sydney, Sydney, Australia; Department of Medicine, Centenary Institute, Sydney, Australia
| | - R Joseph
- Medical Oncology, Mayo Clinic Cancer Center-Florida, Jacksonville
| | - J S Weber
- Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, New York
| | - R Dronca
- Medical Oncology, Mayo Clinic Cancer Center-Florida, Jacksonville
| | - T C Mitchell
- Division of Hematology Oncology, Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia
| | - A Patnaik
- Medical Oncology, South Texas Accelerated Research Therapeutics, San Antonio
| | - H M Zarour
- Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, USA
| | - A M Joshua
- Medical Oncology, Melanoma Institute Australia, Sydney; Medical Oncology, University of Sydney, Sydney, Australia; Kinghorn Cancer Centre, St. Vincent's Hospital, Medical Oncology, Garvan Institute of Medical Research, Sydney; Medical Oncology, University of New South Wales, Sydney, Australia
| | - Q Zhao
- Merck & Co., Inc., Kenilworth
| | | | - S Ahsan
- Merck & Co., Inc., Kenilworth
| | | | - A Ribas
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
| |
Collapse
|
19
|
Hamid O, Ribas A, Daud A, Butler M, Carlino M, Hwu WJ, Long G, Ancell K, Hodi F, Khushalani N, Blank C, Loquai C, Lin J, Diede S, Robert C. Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol 2018; 28:1380-1387. [PMID: 28327988 PMCID: PMC5452069 DOI: 10.1093/annonc/mdx079] [Citation(s) in RCA: 100] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Background The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with KIT-mutated advanced melanoma without prior KIT inhibitor treatment. Patients and methods Forty-two patients with KIT-mutated advanced melanoma were enrolled and treated with nilotinib 400 mg twice daily. TEAM originally included a comparator arm of dacarbazine (DTIC)-treated patients; the design was amended to a single-arm trial due to an observed low number of KIT-mutated melanomas. Thirteen patients were randomized to DTIC before the protocol amendment removing this study arm. The primary endpoint was objective response rate (ORR), determined according to Response Evaluation Criteria In Solid Tumors. Results ORR was 26.2% (n = 11/42; 95% CI, 13.9%–42.0%), sufficient to reject the null hypothesis (ORR ≤10%). All observed responses were partial responses (PRs; median response duration, 7.1 months). Twenty patients (47.6%) had stable disease and 10 (23.8%) had progressive disease; 1 (2.4%) response was unknown. Ten of the 11 responding patients had exon 11 mutations, four with an L576P mutation. The median progression-free survival and overall survival were 4.2 and 18.0 months, respectively. Three of the 13 patients on DTIC achieved a PR, and another patient had a PR following switch to nilotinib. Conclusion Nilotinib activity in patients with advanced KIT-mutated melanoma was similar to historical data from imatinib-treated patients. DTIC treatment showed potential activity, although the low patient number limits interpretation. Similar to previously reported results with imatinib, nilotinib showed greater activity among patients with an exon 11 mutation, including L576P, suggesting that nilotinib may be an effective treatment option for patients with specific KIT mutations. Clinical Trial Registration ClinicalTrials.gov, NCT01028222.
Collapse
Affiliation(s)
- J Guo
- Department of Renal Cancer & Melanona, Peking University Cancer Hospital & Institute, Beijing, China
| | - R D Carvajal
- Division of Hematology/Oncology, Columbia University Medical Center, New York, USA
| | - R Dummer
- Skin Cancer Center, University Hospital of Zurich, Zurich, Switzerland
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany
| | - A Daud
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco
| | - B C Bastian
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco
| | - S N Markovic
- Department of Hematology/Oncology, Mayo Clinic Cancer Center, Rochester, USA
| | - P Queirolo
- Department of Medical Oncology, National Research Institute for Cancer, Genova, Italy
| | - A Arance
- Department of Medical Oncology, Hospital Clinic, Barcelona, Spain
| | - C Berking
- Department of Dermatology & Allergology, University Hospital Munich (LMU), Munich, Germany
| | - V Camargo
- Department of Medical Oncology, Cancer Institute of São Paulo, São Paulo
| | - D Herchenhorn
- Department of Clinical Oncology, National Institute of Cancer, Rio de Janeiro, Brazil
| | - T M Petrella
- Department of Medical Oncology, Sunnybrook Health Sciences Center, Toronto, Canada
| | - D Schadendorf
- Department of Dermatology, Essen University Hospital, Essen, Germany
| | - W Sharfman
- Department of Oncology & Dermatology, Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Medicine, Lutherville, USA
| | - A Testori
- Melanoma and Muscle Cutaneous Sarcoma Division, European Institute of Oncology, Milano, Italy
| | - S Novick
- Oncology Business Unit, Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - S Hertle
- Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland
| | - C Nourry
- Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland
| | - Q Chen
- Oncology Business Unit, Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - F S Hodi
- Melanoma Center, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
21
|
Baharuddin A, Daud A, Abdullah T, Hatta M. The findings of escherichia coli in drinking water with reverse transcriptase polymerase chain reaction method at 16s RNA Gene. Ind Jour of Publ Health Rese & Develop 2018; 9:465. [DOI: 10.5958/0976-5506.2018.01388.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2023]
|
22
|
Baharuddin A, Daud A, Abdullah T, Hatta M. Sociodemographic the characteristics of “Slum and Urban area” Customer behavior depot and identification of escherchia coli with RT-PCR by gen EF-Tu. Ind Jour of Publ Health Rese & Develop 2018; 9:304. [DOI: 10.5958/0976-5506.2018.01471.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2023]
|
23
|
Syamsuar, Daud A, Maria IL, Hatta M, Widyastuti D. Identification of serovar leptospirosis in Flood-Prone areas Wajo District. Ind Jour of Publ Health Rese & Develop 2018; 9:325. [DOI: 10.5958/0976-5506.2018.01019.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2023]
|
24
|
Andtbacka R, Ross M, Agarwala S, Taylor M, Vetto J, Neves R, Daud A, Khong H, Ungerleider R, Tanaka M, Grossmann K. Subgroup analysis of a phase II multicenter trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in unresectable or metastatic melanoma patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Xu W, Frederickson J, Callahan J, Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski T, Puzanov I, Daud A, Colburn D, Choong N, Wongchenko M, Hicks R, McArthur G. Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Daud A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi F, Schachter J, Sosman J, Pavlick A, Gonzalez R, Blank C, Cranmer L, O’Day S, Salama A, Margolin K, Yang J, Homet Moreno B, Ibrahim N, Ribas A. Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Powderly J, Patel M, Lee J, Brody J, Meric-Bernstam F, Hamilton E, Ponce Aix S, Garcia-Corbacho J, Bang YJ, Ahn MJ, Rha S, Kim KP, Gil Martin M, Wang H, Lazorchak A, Wyant T, Ma A, Agarwal S, Tuck D, Daud A. CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.007] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Olszanski A, Gonzalez R, Corrie P, Pavlick A, Middleton M, Lorigan P, Plummer R, Skaria S, Herbert C, Gore M, Agarwala S, Daud A, Zhang S, Bahamon B, Rangachari L, Hoberman E, Kneissl M, Rasco D. Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Affiliation(s)
- A Daud
- Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei
| | - S Johar
- Department of Medicine, Division of Cardiology, RIPAS Hospital, Bandar Seri Begawan, Brunei
| | - K C Lim
- Department of Radiology, RIPAS Hospital, Bandar Seri Begawan, Brunei
| | - V H Chong
- Department of Medicine, RIPAS Hospital, Bandar Seri Begawan, Brunei
| |
Collapse
|
30
|
Mallongi A, Daud A, Ishak H, Ane RL, Birawida AB, Ibrahim E, Selomo M, Rahman SA. Clean Water Treatment Technology with an Up-flow Slow Sand
Filtration System from a Well Water Source in the Tallo District
of Makassar. ACTA ACUST UNITED AC 2016. [DOI: 10.3923/jest.2017.44.48] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Andtbacka R, Ross M, Agarwala S, Taylor M, Vetto J, Neves R, Daud A, Khong H, Ungerleider R, Welden S, Tanaka M, Grossmann K. Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.41] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer L, Robert C, Pavlick A, Gonzalez R, Hodi F, Ascierto P, Salama A, Margolin K, Gangadhar T, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.02] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Yap LB, Nguyen STB, Qadir F, Ma SK, Muhammad Z, Koh KW, Ali Z, Tay GS, Daud A, Said A, Sahat N, Rebo R, Tamin SS, Hussin A, Kaur S, Omar R. A comparison of long-term outcomes between narrow and broad QRS complex patients treated with cardiac resynchronization therapy. Acta Cardiol 2016; 71:323-330. [PMID: 27594128 DOI: 10.2143/ac.71.3.3152093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
34
|
Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol 2016; 27:947-52. [PMID: 26903311 DOI: 10.1093/annonc/mdw044] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 01/27/2016] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Treatment options for sarcoma are limited. Histone deacetylase inhibitors increase the efficacy of topoisomerase II inhibitors by promoting access to chromatin and by down-regulating DNA repair. Thus, combined panobinostat and epirubicin therapy was evaluated to treat refractory sarcoma. PATIENTS AND METHODS Patients with advanced solid tumors were enrolled in a 3 + 3 dose-escalation phase I trial of panobinostat given on days 1, 3, and 5 followed by 75 mg/m(2) of epirubicin on day 5 in 21-day cycles, with a dose expansion at maximum tolerated dose (MTD) in 20 sarcoma patients. Peripheral blood mononucleocyte histone acetylation was also evaluated. RESULTS Forty patients received 20-60 mg panobinostat. Dose-limiting toxicities included thrombocytopenia, febrile neutropenia, and fatigue at 60 mg, defining a panobinostat MTD at 50 mg. Four responses were seen in 37 assessable patients, all after progression on prior topoisomerase II inhibitors. For those with sarcoma, 12 of 20 derived clinical benefit (1 partial response and 11 stable disease, median overall survival 8.3 months), including 8 of 14 previously progressed on topoisomerase II therapy. Treatment benefits correlated with increased histone acetylation and decreased neutrophil count on day 5. CONCLUSIONS Panobinostat and epirubicin treatment is well tolerated and may reverse anthracycline resistance. Changes in histone acetylation and associated decrease in neutrophil count correlated with clinical benefit and warrant investigation as predictive biomarkers. CLINICAL TRIAL This trial is registered at www.Clinicaltrials.gov, Identifier: NCT00878904.
Collapse
Affiliation(s)
- S Thomas
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - R Aggarwal
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - T Jahan
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - C Ryan
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - T Troung
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - A M Cripps
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - P Raha
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - K T Thurn
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - S Chen
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - J A Grabowsky
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - J Park
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - J Hwang
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - A Daud
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| | - P N Munster
- Department of Medicine/Hematology and Oncology, University of California, San Francisco, San Francisco, USA
| |
Collapse
|
35
|
McElroy LM, Woods DM, Yanes AF, Skaro AI, Daud A, Curtis T, Wymore E, Holl JL, Abecassis MM, Ladner DP. Applying the WHO conceptual framework for the International Classification for Patient Safety to a surgical population. Int J Qual Health Care 2016; 28:166-74. [PMID: 26803539 DOI: 10.1093/intqhc/mzw001] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2015] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVE Efforts to improve patient safety are challenged by the lack of universally agreed upon terms. The International Classification for Patient Safety (ICPS) was developed by the World Health Organization for this purpose. This study aimed to test the applicability of the ICPS to a surgical population. DESIGN A web-based safety debriefing was sent to clinicians involved in surgical care of abdominal organ transplant patients. A multidisciplinary team of patient safety experts, surgeons and researchers used the data to develop a system of classification based on the ICPS. Disagreements were reconciled via consensus, and a codebook was developed for future use by researchers. RESULTS A total of 320 debriefing responses were used for the initial review and codebook development. In total, the 320 debriefing responses contained 227 patient safety incidents (range: 0-7 per debriefing) and 156 contributing factors/hazards (0-5 per response). The most common severity classification was 'reportable circumstance,' followed by 'near miss.' The most common incident types were 'resources/organizational management,' followed by 'medical device/equipment.' Several aspects of surgical care were encompassed by more than one classification, including operating room scheduling, delays in care, trainee-related incidents, interruptions and handoffs. CONCLUSIONS This study demonstrates that a framework for patient safety can be applied to facilitate the organization and analysis of surgical safety data. Several unique aspects of surgical care require consideration, and by using a standardized framework for describing concepts, research findings can be compared and disseminated across surgical specialties. The codebook is intended for use as a framework for other specialties and institutions.
Collapse
Affiliation(s)
- L M McElroy
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - D M Woods
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - A F Yanes
- Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - A I Skaro
- Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - A Daud
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - T Curtis
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - E Wymore
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - J L Holl
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - M M Abecassis
- Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - D P Ladner
- Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
36
|
Jayadipraja E, Daud A, Assegaf A, Maming M. The application of the AERMOD model in the environmental health to identify the dispersion area of total suspended particulate from cement industry stacks. ACTA ACUST UNITED AC 2016. [DOI: 10.18203/2320-6012.ijrms20161757] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
37
|
Bhatia S, Iyer J, Ibrani D, Blom A, Byrd D, Parvathaneni U, Diep T, Le M, Pierce R, Heller R, Daud A, Nghiem P. 504 Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30306-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM, Zhu M, Qian J, McKee M, Luo Y, Giranda VL, McArthur GA. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol 2015. [PMID: 26202595 DOI: 10.1093/annonc/mdv308] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Veliparib (ABT-888) is a potent, orally bioavailable, small-molecule inhibitor of the DNA repair enzymes poly ADP-ribose polymerase-1 and -2. Veliparib enhances the efficacy of temozolomide (TMZ) and other cytotoxic agents in preclinical tumor models. PATIENTS AND METHODS In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily. Efficacy end points included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). RESULTS Patients (N = 346) were randomized between February 2009 and January 2010. Median [95% confidence interval (CI)] PFS was 3.7 (3.0-5.5), 3.6 (1.9-4.1), and 2 (1.9-3.7) months in the 20-mg, 40-mg, and placebo arms, respectively. Median (95% CI) OS was 10.8 (9.0-13.1), 13.6 (11.4-15.9), and 12.9 (9.8-14.3) months, respectively; ORR was 10.3%, 8.7%, and 7.0%. Exploratory analyses showed patients with low ERCC1 expression had longer PFS when TMZ was combined with veliparib. Toxicities were as expected for TMZ. The frequencies of thrombocytopenia, neutropenia, and leukopenia were significantly increased in the veliparib groups. Grade 3 or 4 adverse events, mainly hematologic toxicities, were seen in 55%, 63%, and 41% of patients in the 20-mg, 40-mg, and placebo arms, respectively. CONCLUSIONS Median PFS with 20 and 40 mg veliparib almost doubled numerically compared with placebo, but the improvements did not reach statistical significance. OS was not increased with veliparib. Toxicities were similar to TMZ monotherapy, but with increased frequency.
Collapse
Affiliation(s)
- M R Middleton
- Department of Oncology, University of Oxford, Churchill Hospital, Oxford, UK
| | - P Friedlander
- Hematology and Medical Oncology, The Mount Sinai Medical Center, New York
| | - O Hamid
- Experimental Therapeutics/Immunotherapy, The Los Angeles Clinic and Research Institute, Los Angeles
| | - A Daud
- University of California San Francisco Medical Center, University of California, San Francisco, USA
| | - R Plummer
- Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | | | - B Chyla
- AbbVie Inc., North Chicago, USA
| | - F Jiang
- AbbVie Inc., North Chicago, USA
| | | | | | - M Zhu
- AbbVie Inc., North Chicago, USA
| | - J Qian
- AbbVie Inc., North Chicago, USA
| | - M McKee
- AbbVie Inc., North Chicago, USA
| | - Y Luo
- AbbVie Inc., North Chicago, USA
| | | | - G A McArthur
- Divisions of Cancer Medicine/Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia
| |
Collapse
|
39
|
|
40
|
Robert C, Mateus C, Hodi S, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu WJ, Gangadhar TC, Patnaik A, Joshua AM, Hersey P, Weber J, Dronca R, Zarour H, Gergich K, Li XN, Lannone R, Kang SP, Ebbinghaus S, Ribas A. Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
41
|
Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol 2014; 26:415-21. [PMID: 25411413 DOI: 10.1093/annonc/mdu529] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Pyrexia is a frequent adverse event with combined dabrafenib and trametinib therapy (CombiDT), but little is known of its clinical associations, etiology, or appropriate management. PATIENTS AND METHODS All patients on the BRF133220 phase I/II trial of CombiDT treated at the standard dose (150/2) were included for assessment of pyrexia (n = 201). BRAF and MEK inhibitor-naïve patients (n = 117) were included for efficacy analyses. Pyrexia was defined as temperature ≥38°C (≥100.4(°)F) or related symptoms. RESULTS Fifty-nine percent of patients developed pyrexia during treatment, 24% of which had pyrexia symptoms without a recorded elevation in body temperature. Pyrexia was grade 2+ in 60% of pyrexia patients. Median time to onset of first pyrexia was 19 days, with a median duration of 9 days. Pyrexia patients had a median of two pyrexia events, but 21% had three or more events. Various pyrexia management approaches were conducted in this study. A trend was observed between dabrafenib and hydroxy-dabrafenib exposure and pyrexia. No baseline clinical characteristics predicted pyrexia, and pyrexia was not statistically significantly associated with treatment outcome. CONCLUSIONS Pyrexia is a frequent and recurrent toxicity with CombiDT treatment. No baseline features predict pyrexia, and it is not associated with clinical outcome. Dabrafenib and metabolite exposure may contribute to the etiology of pyrexia. The optimal secondary prophylaxis for pyrexia is best studied in a prospective trial.
Collapse
Affiliation(s)
- A M Menzies
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia
| | - M T Ashworth
- University of California San Francisco, San Francisco
| | - S Swann
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - R F Kefford
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia Westmead Hospital, University of Sydney, Sydney Westmead Millennium Institute, University of Sydney, Sydney, Australia
| | - K Flaherty
- Massachusetts General Hospital Center, Boston
| | - J Weber
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa
| | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - K B Kim
- California Pacific Medical Center, San Francisco
| | - R Gonzalez
- Department of Medical Oncology, The University of Colorado Cancer Center, Aurora
| | - O Hamid
- Department of Oncology, The Angeles Clinic and Research Institute, Santa Monica
| | - L Schuchter
- Penn Medicine, The University of Pennsylvania, Philadelphia, USA
| | - J Cebon
- Oncology Unit, Ludwig Institute for Cancer Research, Heidelberg, Australia
| | - J A Sosman
- Department of Oncology, Vanderbilt University Medical Centre, Nashville, USA
| | - S Little
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - P Sun
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - G Aktan
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - D Ouellet
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - F Jin
- Clinical Statistics, GlaxoSmithKline, Collegeville, USA
| | - G V Long
- Melanoma Institute Australia and The University of Sydney, Sydney, Australia Westmead Millennium Institute, University of Sydney, Sydney, Australia
| | - A Daud
- University of California San Francisco, San Francisco
| |
Collapse
|
42
|
Daud A, Hamid O, Robert C, Hodi F, Wolchok J, Hwu W, Weber J, Kefford R, Hersey P, Joshua A, Joseph R, Gangadhar T, Dronca R, Patnaik A, Zarour H, Gerigich K, Lunceford J, Emancipator K, Dolled-Filhart M, Li X, Kang P, Ebbinghaus S, Ribas A. 140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475). Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70266-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
43
|
Robert C, Joshua A, Weber J, Ribas A, Hodi F, Kefford R, Daud A, Wolchok J, Hwu WJ, Gangadhar T, Patnaik A, Hersey P, Dronca R, Zarour H, Ge Y, Lindia J, Giannotti M, Ebbinghaus S, Kang S, Hamid O. Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu438.42] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol 2013; 73:103-11. [DOI: 10.1007/s00280-013-2324-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 10/11/2013] [Indexed: 10/26/2022]
|
45
|
Abstract
Background: Moringa gum obtained from stem of the plant Moringa oleifera Lam. belonging to family Moringaceae. Number of naturally occurring polysaccharides obtained from plant (guar gum, inulin), animal (chitosan, chondrotin sulphate), algal (alginates) or microbial (dextran) origin. Objective: The present study was evaluated Moringa oleifera gum as a carrier for colon specific drug delivery using in vitro drug release studies. Materials and Methods: Six formulations of curcumin were prepared using varying concentration of Moringa oleifera gum containing 50 mg curcumin by wet granulation method. Tablets were subjected for evaluation by studying the parameter like hardness, friability, drug content uniformity and in vitro drug release study. Hardness was found to be in the range of 5.5 to 7.3 kg/cm2, the percentage friability was in the range of 0.60 to 0.89%, and tablet showed 98.99% to 99.89% of the labeled amount of curcumin indicating uniformity in drug content. Results and Discussion: In vitro drug release study was performed using simulated stomach, intestinal and colonic fluid. The susceptibility of Moringa gum to colonic bacteria was also assessed using drug release study with rat caecal contents. 30% Moringa gum containing formulation (F-3) was shown better drug released that is 90.46%, at the end of 24 h of dissolution study in the presence of rat caecal contents in comparison to 40% Moringa gum containing formulation (F-4) that was 78.03%. Conclusion: The results illustrate the usefulness of Moringa olefera gum as a potential carrier for colon-specific drug delivery.
Collapse
Affiliation(s)
- Anil Kumar Singhal
- Unijules Life Sciences Research Lab. TIFAC-CORE In Green Pharmacy, B. R. Nahata College of Pharmacy, BRNSS-Contract Research Center, Madhya Pradesh, India
| | | | | | | |
Collapse
|
46
|
Munster P, van der Noll R, Voest E, Specht J, Werner T, Dees E, Tan A, Daud A, Schellens J, Lolkema M, Griffin M, Agarwal N, Falchook G, Kleha J, Durante M, Smith D, Adams L, Greshock J, Morris S, Kurzrock R. PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33038-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
47
|
Gonzalez R, Ribas A, Daud A, Pavlick A, Gajewski T, Puzanov I, Teng M, Chan I, Choong N, McArthur G. Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34336-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
48
|
Daud A, Gaikwad N, Sapkal N, Bonde M. To study the effect of solvent, viscosity, and temperature on the mouth-dissolving film of Withania somnifera Linn. Asian J Pharm 2012. [DOI: 10.4103/0973-8398.104838] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Munster PN, van der Noll R, Voest EE, Dees EC, Tan AR, Specht JM, Falchook GS, Daud A, Lolkema MP, Grilley-Olson JE, Yu EY, Fu S, Bergsland EK, Kleha J, Peng S, Smith DA, Lampkin TA, Schellens JHM, Morris SR, Kurzrock R. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3018] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Gordon MS, Vogelzang NJ, Schoffski P, Daud A, Spira AI, O'Keeffe BA, Rafferty T, Lee Y, Berger R, Shapiro G. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3010] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|